Published in Medical Letter on the CDC and FDA, June 29th, 2008
This compound is a biogenic amine reuptake inhibitor acting at multiple targets, which may represent a new class of therapeutic agent that could lead to an improved treatment for depression or other...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA